Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Type Condition

    Atlanta, GA

    Search
    Atlanta, GA
    Show Map
    Map View
    Atlanta, GA
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      183 Clinical Paid Trials near Atlanta, GA

      Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Gene Therapy for Fabry Disease

      Atlanta, Georgia
      This trial tests ST-920, a treatment using a virus to deliver a gene that helps produce an important enzyme in patients with Fabry disease. The goal is to help these patients by continuously making the enzyme to reduce harmful substances in their bodies. ST-920 is a gene therapy treatment for Fabry disease, which aims to deliver a gene to produce the enzyme alpha-galactosidase A, addressing the enzyme deficiency central to the disease.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      34 Participants Needed

      CX-4945 for Medulloblastoma

      Atlanta, Georgia
      This trial tests an oral drug called CX-4945 for patients with a recurring type of brain tumor. The drug aims to block a protein that helps cancer cells grow. The study will determine the best dose and check for side effects. CX-4945 has shown promising results in other types of cancer and may be developed as a new therapy.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:3+

      Key Eligibility Criteria

      Disqualifiers:Nursing Mothers, Other Malignancy, Gastrointestinal Disorders, Others
      Must Not Be Taking:Warfarin, Statins

      66 Participants Needed

      Vorinostat for Graft-versus-Host Disease Prevention

      Atlanta, Georgia
      The purpose of this study is to determine the recommended phase 2 dose of the drug Vorinostat in children, adolescents and young adults following allogeneic blood or marrow transplant (BMT) and determine whether the addition of Vorinostat to the standard graft versus host disease (GVHD) prophylaxis will reduce the incidence of GVHD.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:3 - 39

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Illness, HIV, Hepatitis, Others
      Must Not Be Taking:Valproic Acid

      43 Participants Needed

      Quizartinib for Acute Myeloid Leukemia

      Atlanta, Georgia
      Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research. Children or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or is not responding to treatment.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:1 - 21

      Key Eligibility Criteria

      Disqualifiers:CNS Relapse, APL, HIV, Others
      Must Not Be Taking:Chemotherapy, Radiation, Immunotherapy, Others

      65 Participants Needed

      Stem Cell Transplant for Sickle Cell Disease

      Atlanta, Georgia
      This is an open label, multicenter, Phase 1/2 study in approximately eight adults with severe Sickle Cell Disease (SCD). The study will evaluate the safety, tolerability, and efficacy of autologous hematopoietic stem cell transplantation using BIVV003.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:18 - 40

      Key Eligibility Criteria

      Disqualifiers:Organ Dysfunction, Active Malignancy, HIV, Others
      Must Not Be Taking:Prohibited Medications

      8 Participants Needed

      Pembrolizumab + Pralatrexate for Peripheral T-Cell Lymphoma

      Atlanta, Georgia
      This trial studies the combination of pralatrexate and pembrolizumab in patients with peripheral T-cell lymphomas that have returned or not responded to treatment. Pralatrexate blocks cancer cell growth, while pembrolizumab boosts the immune system to attack cancer cells. The goal is to find the best dose and see how well this combination works.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:HIV, Hepatitis B/C, Autoimmune, Others
      Must Be Taking:Vitamin B12, Folic Acid

      13 Participants Needed

      Cabotegravir + Rilpivirine for HIV Infection

      Atlanta, Georgia
      This trial tests new HIV medications in pill and injection forms for children and teens. The medications work by stopping the virus from growing.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:12 - 17

      Key Eligibility Criteria

      Disqualifiers:Cardiac Disease, Tuberculosis, Hepatitis, Others
      Must Be Taking:Antiretrovirals

      168 Participants Needed

      TAS-102 + Nanoliposomal Irinotecan for Gastrointestinal Cancer

      Atlanta, Georgia
      This phase I/II trial studies the best dose and how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) and nanoliposomal irinotecan work in treating patients with gastrointestinal cancers that have spread to other places in the body (metastatic) or cannot be removed by surgery. Drugs used in the chemotherapy, such as trifluridine/tipiracil hydrochloride combination agent TAS-102 and nanoliposomal irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Second Malignancy, Heart Failure, CNS Metastases, Others
      Must Not Be Taking:Irinotecan, Investigational Therapy

      64 Participants Needed

      Chemotherapy + Rucaparib for Digestive System Cancers

      Atlanta, Georgia
      This phase I/II trial studies the side effects and best dose of liposomal irinotecan and rucaparib when given together with fluorouracil and leucovorin calcium and to see how well they work in treating patients with pancreatic, colorectal, gastroesophageal, or biliary cancer that has spread to other places in the body (metastatic). Chemotherapy drugs, such as liposomal irinotecan, fluorouracil, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as rucaparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Giving liposomal irinotecan and rucaparib together with fluorouracil and leucovorin calcium may work better in treating patients with pancreatic, colorectal, gastroesophageal, or biliary cancer.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, HIV, Uncontrolled Illness, Others
      Must Not Be Taking:Antiretrovirals, PARP Inhibitors

      18 Participants Needed

      Gene Therapy for SCID

      Atlanta, Georgia
      This is a phase I/II open label multi-center study in which patients will receive low dose targeted busulfan followed by infusion of autologous CD34+ selected bone marrow or mobilized peripheral blood cells transduced with the G2SCID vector. Subjects will be enrolled over 3 years and be followed for 2 years post-infusion on this protocol, then followed long-term on a separate long-term follow-up protocol. Enrollment of subjects will be agreed upon by representatives of both sites. Data will be collected uniformly from both sites through an electronic capture system and key laboratory studies will be centralized. Harvest, cellular manufacturing and infusion will occur at each site using the same SOPs. Key aspects of cellular product characterization will be centralized
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2
      Age:0 - 5
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Active Infection, Seizure Disorder, Encephalopathy, DNA Repair Disorder, Others

      12 Participants Needed

      Vaxchora Vaccine for Cholera

      Atlanta, Georgia
      The primary objective of this study is to evaluate the antibody response to the cholera vaccine, Vaxchora®, in healthy subjects. Investigators also seek to evaluate additional markers of the adaptive immune response including plasmablasts, activated B cells, memory B cells, and T cell responses in healthy subjects receiving cholera vaccine, produce monoclonal antibodies against cholera, and evaluate the safety and reactogenicity in healthy subjects receiving cholera vaccine.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:18 - 49

      Key Eligibility Criteria

      Disqualifiers:Autoimmune Disease, Immunosuppression, Small Bowel Disease, Others
      Must Not Be Taking:Corticosteroids, Antibiotics, Blood Thinners, Others

      34 Participants Needed

      Nivolumab + Lenalidomide for Lymphoma

      Atlanta, Georgia
      This trial studies the combination of lenalidomide and nivolumab for patients with non-Hodgkin or Hodgkin lymphoma that has come back and does not respond to treatment. Lenalidomide works by killing or stopping the growth of cancer cells, while nivolumab helps the immune system attack the cancer. The goal is to find the best dose and see how well this combination works. Lenalidomide has shown significant activity in some subtypes of lymphoma, and combining it with other treatments like rituximab has been promising.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Active Infection, Autoimmune Disease, Cardiovascular Disease, Others
      Must Not Be Taking:Immunosuppressants, Steroids

      36 Participants Needed

      JSP191 for Severe Combined Immunodeficiency (SCID)

      Atlanta, Georgia
      This trial tests JSP191, an antibody, in SCID patients needing a blood stem cell transplant. JSP191 helps by clearing out old blood-forming cells to make room for new, healthy ones.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:3 - 12

      Key Eligibility Criteria

      Disqualifiers:Acute Infections, Active Malignancies, Others
      Must Not Be Taking:Investigational Agents, Chemotherapy

      40 Participants Needed

      TAK-788 for Non-Small Cell Lung Cancer

      Atlanta, Georgia
      This study is about a medicine called TAK-788, also known as mobocertinib, given to adults with non-small cell lung cancer. The main aims of this study are to check if there are any side effects from TAK-788, to learn how TAK-788 is processed by the body, and to determine the best dose of TAK-788 to treat this condition. Participants will take TAK-788 capsules with chemotherapy. Participants will continue to take TAK-788 unless they or their doctor decide they should stop this treatment. Participants will take TAK-788 capsules with or without chemotherapy under antidiarrhea prevention to determine the safety of TAK-788 treatment. Non-Asian, non-White participants will take TAK-788 to determine the safety and tolerability of TAK-788 treatment.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Other Malignancy, CNS Metastases, Others
      Must Not Be Taking:CYP3A Inhibitors, CYP3A Inducers

      334 Participants Needed

      ASTX660 for Cancer

      Atlanta, Georgia
      This trial is testing ASTX660, a new drug for patients with advanced cancers who have no other treatment options. It works by blocking proteins that help cancer cells survive, making it easier to kill them.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Cardiac Disease, HIV, Hepatitis, Others
      Must Not Be Taking:QT Prolonging Drugs

      230 Participants Needed

      Arginine Therapy for Sickle Cell Disease

      Atlanta, Georgia
      The purpose of this study is to determine whether giving extra arginine to patients with sickle cell disease seeking treatment for vaso-occlusive painful events (VOE) will decrease pain scores, decrease need for pain medications or decrease length of hospital stay or emergency department visit.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2
      Age:7 - 21

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Renal Dysfunction, Stroke, Others
      Must Not Be Taking:Inhaled Nitric Oxide, Sildenafil

      21 Participants Needed

      Brentuximab Vedotin + Nivolumab ± Ipilimumab for Hodgkin's Lymphoma

      Atlanta, Georgia
      This phase I/II trial studies the side effects and best dose of ipilimumab and nivolumab when given together with brentuximab vedotin, and how well they work in treating patients with Hodgkin lymphoma that has returned after a period of improvement (recurrent) or has not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. It is not known whether giving brentuximab vedotin and nivolumab with or without ipilimumab may kill more cancer cells.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Autoimmune Disorders, CNS Involvement, Others
      Must Not Be Taking:Systemic Corticosteroids

      146 Participants Needed

      Belantamab + Isatuximab for Multiple Myeloma

      Atlanta, Georgia
      The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with isatuximab, and to establish the recommended Phase 2 dose (RP2D) for the combination treatment to explore in the cohort expansion (CE) phase in participants with RRMM. This study is a sub study of the Master protocol (NCT04126200).
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      30 Participants Needed

      Belantamab Mafodotin + Feladilimab for Multiple Myeloma

      Atlanta, Georgia
      The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with feladilimab (GSK3359609), and to establish the recommended Phase 2 dose (RP2D) for the combination treatment to explore in the cohort expansion (CE) phase in participants with RRMM. This study is a sub study of the Master protocol (NCT04126200).
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      25 Participants Needed

      Baricitinib for HIV Infection

      Atlanta, Georgia
      This study is being done to test whether a drug called baricitinib, which blocks specific causes of inflammation, affects HIV-1 viral rebound and viral load levels after HIV treatment is discontinued. Researchers will test the effects of continuing baricitinib in people with HIV before and after discontinuing their antiretroviral therapy. This drug is approved by the Food and Drug Administration (FDA) for other diseases; it is not approved for the treatment of HIV-1. The study team will also investigate any side effects associated with the drug.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:AIDS, Cardiovascular Disease, Cancer, Others
      Must Be Taking:Antiretrovirals

      20 Participants Needed

      Why Other Patients Applied

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58
      Match to a Trial

      CDI-988 for Norovirus

      Decatur, Georgia
      Participants in this study will be given either CDI-988 or placebo orally before receiving a norovirus challenge virus and continuing for 5 days. Participants will not know whether they are getting placebo or CDI-988. The study will evaluate how well CDI-988 compared to placebo can reduce the incidence of clinical symptoms after a challenge with norovirus. The amount of virus in stool samples will be measured over time. Side effects and pharmacokinetics (the amount of CDI-988 in blood) will also be measured.

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 1, 2
      Age:18 - 49

      Key Eligibility Criteria

      Disqualifiers:Norovirus History, GI Disorders, Others
      Must Not Be Taking:Immunosuppressants, High-dose Steroids

      40 Participants Needed

      Flu Vaccine for Flu

      Atlanta, Georgia
      "The purpose of this study is to assess the reactogenicity, safety and immune response of GlaxoSmithKlines (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine candidates administered in healthy younger and older adults."
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Immunosuppressive Conditions, Guillain-Barré, Others
      Must Not Be Taking:Immune-modifying Drugs, Anti-tumoral Medication

      776 Participants Needed

      Belantamab Mafodotin + Nirogacestat for Multiple Myeloma

      Atlanta, Georgia
      The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with nirogacestat and to establish the recommended Phase 2 dose for combination treatment to explore in the cohort expansion (CE) phase in participants with RRMM. This study is a sub study of the Master protocol (NCT04126200).
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      106 Participants Needed

      Sacituzumab Govitecan for Breast Cancer

      Atlanta, Georgia
      The goal of this clinical study is to learn more about the study drug sacituzumab govitecan-hziy (SG) given at an alternative dose and schedule, in participants with triple-negative breast cancer (TNBC). The primary objectives of this study are to assess the safety and tolerability of SG given at alternate dose and schedule, to assess the effect on objective response rate (ORR) and progression-free survival (PFS).
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Prior Topoisomerase Inhibitors, Trop-2 ADCs
      Must Not Be Taking:Topoisomerase Inhibitors, Trop-2 ADCs

      100 Participants Needed

      mRNA Vaccine for Flu

      Decatur, Georgia
      The purpose of this phase 1/2 study is to investigate the safety and immunogenicity of different doses (high, medium and low) of a second generation structurally designed (SD2) H5 messenger ribonucleic acid (mRNA) vaccine against pandemic H5 influenza virus (pandemic flu H5 hemagglutinin (HA) mRNA SD2) in healthy younger and older adults. The study will aim to identify the appropriate dose for further clinical development of a potential pandemic response vaccine. The study duration per participant will be approximately 13 months. There will be two injections of placebo or pandemic flu H5 mRNA vaccine 21 days apart at high, medium and low doses. Study visits/contact include: 7 study visits and 1 telephone call. Vaccination visits (including blood samples) will occur at Day 01 and Day 22. Short-term follow-up visits (including blood samples) will occur 8 and 21 days after each injection. Participants will be also followed up (including blood samples) at 3 and 6 months after 2nd injection, and at 12 months after 2nd injection for safety.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Immunodeficiency, Myocarditis, Guillain-Barré, Others
      Must Not Be Taking:Immunosuppressants, Corticosteroids, Anticoagulants, Others

      240 Participants Needed

      BNT323 + BNT327 for Breast Cancer

      Atlanta, Georgia
      This is a Phase I/II, multi-site, open-label, two-part study designed to evaluate the efficacy, safety, optimized dose and contribution of components of BNT323 in combination with BNT327 in participants with hormone receptor-positive (HR+) or hormone receptor-negative (HR-), Human epidermal growth factor receptor (HER)2-positive, HER2-low (immunohistochemistry \[IHC\] 1+ or IHC 2+/in situ hybridization -), HER2-ultralow (IHC 0, with membrane staining) or HER2-null breast cancer (BC), or triple-negative breast cancer (TNBC).
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Small Bowel Obstruction, Uncontrolled Illness, ILD/pneumonitis, Others
      Must Not Be Taking:Topoisomerase Inhibitors, PD-L1/VEGF, Immunostimulatory Agents, Systemic Corticosteroids

      380 Participants Needed

      Flu Vaccine for Influenza

      Decatur, Georgia
      The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular injection of different formulations of a hexavalent influenza messenger ribonucleic acid (mRNA) vaccine composed of differing dose levels of trivalent (TIV) mRNA hemagglutinin (HA) in combination with TIV mRNA-neuraminidase (NA) compared to an active control ((Fluzone standard-dose quadrivalent influenza vaccine (QIV-SD) or Fluzone high-dose quadrivalent influenza vaccine (QIV-HD) in adults 50 years of age and older.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:50+

      Key Eligibility Criteria

      Disqualifiers:Immunodeficiency, Myocarditis, Guillain-Barré, Others
      Must Not Be Taking:Immunosuppressants, Corticosteroids, Anticoagulants, Others

      1162 Participants Needed

      mRNA Vaccine for Flu

      Atlanta, Georgia
      The purpose of this study is to evaluate a pandemic flu H5 strain messenger ribonucleic acid (mRNA) vaccine at 3 dose levels (low, medium, and high) in comparison with placebo in 276 healthy adult participants to select the adequate dose for further clinical development. The duration per participant will be approximately 13 months.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Immunodeficiency, Myocarditis, Guillain-Barré, Others
      Must Not Be Taking:Immunosuppressants, Corticosteroids, Anticoagulants, Others

      276 Participants Needed

      Combination Vaccine for COVID-19 and Flu

      Atlanta, Georgia
      Study VBT00001 is planned to be a Phase 1/2, randomized, modified double-blind, active-controlled, multi-center study to be conducted in approximately 980 adults aged 50 years and older in the United States. The purpose of the study is to assess the safety and immunogenicity of IIV-HD (high-dose inactivated influenza vaccine) + rC19 (adjuvanted recombinant COVID-19 vaccine) vaccine comprised of IIV-HD combined with different recombinant Spike (rS) antigen levels of rC19 compared to IIV-HD alone, rC19 (dose 1) alone, and IIV-HD and rC19 (dose 1) (coadministered in opposite arms). Placebo will be coadministered in the IIV-HD alone, rC19 (dose 1) alone, and IIV-HD + rC19 study groups to control for the number of injections and to maintain observer-blinding. Thus, each participant will receive two injections at enrollment, one in each deltoid muscle. Study details include: * The study duration will be approximately 12 months * Study intervention will be administered via a single intramuscular (IM) injection into the right and left deltoid muscles on D01 * Dose escalation with sequential enrollment (sentinel cohort followed by main cohort for a given dose) * The visit frequency will be D01, D09 (telephone call), D30, D182 (telephone call), and D366 (telephone call) Number of Participants: Approximately 980 participants are expected to be randomized.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:50+

      Key Eligibility Criteria

      Disqualifiers:Immunodeficiency, Bleeding Disorder, Stroke, Others
      Must Not Be Taking:Immunosuppressants, Anticoagulants

      980 Participants Needed

      Azithromycin for Meningococcal Disease

      Decatur, Georgia
      The purpose of this study is to determine the effectiveness of azithromycin in the eradication of nasopharyngeal carriage of N. meningitidis
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:18 - 25

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Breastfeeding, Allergic Reactions, Others
      Must Not Be Taking:Systemic Antibiotics

      1120 Participants Needed

      1...4567

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do clinical trials in Atlanta, GA pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do clinical trials in Atlanta, GA work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in Atlanta, GA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Atlanta, GA is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Atlanta, GA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a medical study in Atlanta, GA?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest clinical trials in Atlanta, GA?

      Most recently, we added LevoCept for Birth Control, Ruxolitinib for Sickle Cell Disease and Prophylactic Transfusion for Sickle Cell Disease in Pregnancy to the Power online platform.

      What do the "Power Preferred" and "SuperSite" badges mean?

      We recognize research clinics with these awards when they are especially responsive to patients who apply through the Power online platform. SuperSite clinics are research sites recognized for a high standard of rapid and thorough follow-up with patient applicants. Meanwhile, Power Preferred clinics are the top 20 across the entire Power platform, recognized for their absolute top patient experience.

      Which clinics have received Power Preferred and SuperSite awards in Atlanta, GA?

      The clinics in Atlanta, GA currently recognized as Power Preferred are: CenExel ACMR in Atlanta, Georgia

      Popular Searches

      By Condition

      Depression Clinical Trials in Georgia

      Anxiety Clinical Trials in Georgia

      Schizophrenia Clinical Trials in Georgia

      ADHD Clinical Trials in Georgia

      Bipolar Disorder Clinical Trials in Georgia

      Multiple Sclerosis Clinical Trials in Georgia

      Autism Clinical Trials in Georgia

      Treatment Resistant Depression Clinical Trials in Georgia

      Borderline Personality Disorder Clinical Trials in Georgia

      Social Anxiety Disorder Clinical Trials in Georgia

      Parkinson's Disease Clinical Trials in Georgia

      Alzheimer's Disease Clinical Trials in Georgia

      By Location

      Clinical Trials near Atlanta, GA

      Clinical Trials near Augusta, GA

      Clinical Trials near Decatur, GA

      Clinical Trials near Savannah, GA

      Clinical Trials near Marietta, GA

      Clinical Trials near Columbus, GA

      Clinical Trials near Macon, GA

      Clinical Trials near Lawrenceville, GA

      Clinical Trials near Gainesville, GA

      Clinical Trials near Athens, GA

      Clinical Trials near Roswell, GA

      Clinical Trials near Stockbridge, GA

      Other People Viewed

      By Subject

      Top Clinical Trials near Atlanta, GA

      Top Diabetes Clinical Trials near Atlanta, GA

      31 Psoriasis Trials near Atlanta, GA

      68 Depression Trials near Atlanta, GA

      31 Schizophrenia Trials near Atlanta, GA

      24 Bipolar Disorder Trials near Atlanta, GA

      59 Alzheimer's Disease Trials near Atlanta, GA

      Top Osteoarthritis Clinical Trials near Atlanta, GA

      Top Clinical Trials near Cartersville, GA

      Top Clinical Trials near Canton, GA

      Top Clinical Trials near Alpharetta, GA

      Top Clinical Trials near Adairsville, GA

      By Trial

      Telerehabilitation for Lower Back Pain

      Permissive Hypotension for Surgery

      Virtual Reality Therapy for Sickle Cell Crisis

      Nicorandil for Hippocampal Sclerosis

      Dexmedetomidine for Pediatric Anesthesia

      Pembrolizumab + Sunitinib for Thymic Cancer

      Meaning-Centered Psychotherapy for Cancer Caregiver Support

      [212Pb]VMT-alpha-NET for Neuroendocrine Tumors

      Osteopathic Manipulation for Cognitive Impairment

      INCB040093 + Itacitinib for B-Cell Lymphoma

      Creatine Supplementation for Muscle Strength

      FT536 for Gynecologic Cancers

      Related Searches

      Top Clinical Trials near Pasadena, TX

      Top Clinical Trials near Albuquerque, NM

      Top Clinical Trials near Milwaukee, WI

      Top Lung-cancer Clinical Trials near High Point, NC

      Top Clinical Trials near Columbia, SC

      HIV/HCV Testing for Substance Use Disorder

      Insulin Dosing with Omnipod M System for Type 2 Diabetes

      Top Diabetic-nephropathy Clinical Trials

      Faith-Based Physical Activity Programs for Cardiovascular Health

      Surgery and Radiotherapy for Breast Cancer

      HER2/neu DNA Immunization for Breast Cancer

      Top Clinical Trials near East Hanover, NJ